gastroparesis symptoms glp 1 GLP-1 Gastroparesis: Hidden Dangers Beyond C GLP-1 Gastroparesis: Hidden Dangers Beyond

GLP-1 agonist therapy helps manage type 2 diabetes and supports weight loss

CagriSema is a fixed-dose combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist), and is currently an experimental obesity drug developed by Novo Nordisk

Semaglutide patent expiry in mid-March 2026 set to trigger entry of 50+ branded generics in India: Sheetal Sapale

PlexusDx offers compounded semaglutide injections starting at $149 per month without insurance requirements, providing immediate access to GLP-1 therapy

Walmart now has a GLP-1 support page on its website and its one of the clearest signals yet of where food and wellness are heading

Backed by Science